ChemicalBook Produktkatalog Aktive pharmazeutische Wirkstoffe (APIs) Kreislaufsystem Drogen Antihypertensiva (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID

(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Struktur

(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID

Bezeichnung:(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID

CAS-Nr89396-94-1

Englisch Name:(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID

CBNumberCB81009271

SummenformelC20H27N3O6

Molgewicht405.44488

MOL-Datei89396-94-1.mol

(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID physikalisch-chemischer Eigenschaften

Schmelzpunkt	214-216℃
alpha	D20 -64.1° (c = 0.5 in ethanol)
storage temp.	-20°C
Löslichkeit	H2O: ≥5mg/mL
Aggregatzustand	powder
Farbe	white to tan
Optische Aktivität	[α]/D -50 to -70° in ethanol (c=0.5)
Merck	14,4911

Sicherheit

WGK Germany	3
RTECS-Nr.	NI8927400
HS Code	2933.29.4300

Gefahreninformationscode (GHS)

(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Angiotensin converting enzyme (ACE) inhibitor. Antihypertensive.
Verwenden
Imidapril hydrochloride was used as a standard in bioequivalence test by LC/MS method.
Verwenden
antibiotic
Definition
ChEBI: Imidapril hydrochloride is a dipeptide.
Allgemeine Beschreibung
Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1.
Biochem/physiol Actions
Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive.
Clinical Use
Angiotensin-converting enzyme inhibitor:

Hypertension
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
Bee venom extract: possible severe anaphylactoid reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
Cytotoxics: increased risk of angioedema with everolimus.
Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
Gold: flushing and hypotension with sodium aurothiomalate.
Lithium: reduced excretion, possibility of enhanced lithium toxicity.
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.
Stoffwechsel
Imidapril is a prodrug, and is metabolised in the liver to the diacid imidaprilat, its active metabolite. The bioavailability of imidaprilat is about 42% after oral doses of imidapril.
About 40% of an oral dose is excreted in the urine, the rest in the faeces.

(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

89396-94-1, (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Verwandte Suche:

Send Inquriy